Inhibition of neovascularization using vegf-specific oligonucleo

Details Inhibition of neovascularization using vegf-specific oligonucleo Inhibition of neovascularization using vegf-specific oligonucleo

1995-07-12

1998-09-29

Elliott, George C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

435 6, 435375, 536 245, A61K 3170, C12N 510, C07H 2100, C12Q 168

Patent

active

058146202

ABSTRACT:
Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.

REFERENCES:
Gura, T. "Antisense Has Growing Pains", vol. 270: 575-577, Oct. 27, 1995.
Wu Pong, S. "Oligonucleotides Opportunities for Drug Therapy Research", Pharmaceutical Technology, vol. 18: 102-114, Oct. 1994.
Stull, R. et al "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects", Pharmaceutical Research. vol. 12(4): 465-483, 1995.
Bennet, F. "Antisense Research", Science vol. 271:434, Jan. 26, 1996.
Westermann, B. et al "Inhibition of Expression of SV40 virus large T-antigen byAntisense Oligonucleotides", Biomed. Biochim. Acta. vol. 48: 85-83, 1989.
Milligan, J. "Current Concepts in Antisense Drug Design", J. Medicinal Chemistry. vol. 36(14): 1923-1937, Jul. 9, 1993.
Miller, N. et al "Gene Transfer and Antisense Nucleic Acid Techniques", Parisitology Today. vol. 10(3): 92-97, 1994.
Rojanasakul, Y. "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting", Advanced Drug Delivery Reviews. vol. 18: 115-131, 1996.
Weiss, R. "Upping the Antisense Ante", Science News, vol. 139: 108-109, 1991.
Stein, C. et al. "Antisense Oligonucleotides as Therapeutic Agents --Is the Bullett Magical?" Science vol. 261: 1004-1012, Aug. 20, 1993.
Wagner, R. "Gene Inhibition Using Antisense Oligonucleotides", Nature vol. 372: 333-335, Nov. 24, 1994.
Monia et al. (1993) Journal of Biological Chemistry 268:14514-14522.
Uhlmann et al. (1990) Chemical Reviews 90:543-584.
Detmar et al. (1994) Journal of Experimental Medicine 180:1141-1146.
Pierce et al. (1995) Investigative Opthalmology & Visual Science 36:Abstract 3990.
Smith et al. (1995) Investigative Ophthamology & Visual Science 36:Abstract 3992.
Monacci et al. (1993) American Journal Of Physiology 264:c995-c1002.
Garrido et al. (1993) Growth Factors 8:109-117.
Uchida et al., (1995) Antisense Res. & Dev. 5(1)87 (Abstract OP-10).
Nomura et al., (1995) Antisense Res.& Dev. 5(1):91 (Abstract OP-18).
Michaelson (1948) Trans, Ophthalmol. Soc. U.K. 68:137-180.
Ashton et al. (1954) Br. J. Ophthalmol. 38:397-432.
Am J. Ophthalmol. (1976) 81:383-396.
Knighton et al. (1983) Science 221:1283-1285.
Senger et al. (1986) Cancer Res. 46:5629-5632.
Folkman et al. (1987) Science 235:442-446.
Ophthalmol. (1991) 18:741-840 ( Supplement).
Klagsbrun et al. (1991) Ann. Rev. Physiol. 53:217-239.
Tischer et al. (1991) J. Biol. Chem. 266:11947-11954.
Claffey et al. (1992) J. Biol. Chem. 267:16317-16322.
Plate et al. (1992) Nature 359:845-848.
Plouet et al. (1992) Invest. Ophthamol. Vis. Sci. 34:900.
Schweiki et al. (1992) Nature 359:843-845.
Adamis et al. (1993) Biochem. Biophys. Res. Commun. 193:631-638
Adamis et al. (1993) Invest. Ophthalmol. Vis. Sci 34:1440.
Kim et al. (1993) Nature 362:841-844.
Miller et al. (1993) Principles and Practice of Ophthalmology, W.B. Saunders, Philadelphia, p. 760.
Aiello et al. (1994) New Eng. J. Med. 331:1480-1487.
Aiello et al. (1994) Invest. Ophthalmol. Vis Sci. 35:1868.
Anonymous (1994) Prevent Blindness America.
Bressler et al., Principles and Practice of Ophthalmology (eds. Albert and Jakobiac), W.B. Saunders Co., Philadelphia, PA) (1994) vol. 2 pp. 834-852.
Foster and Harrison's Principles and Practice of Internal Medicine (lsselbacher et al., eds.) McGraw-Hill, Inc. New York (1994) pp. 1994-1995.
Pierce et al. (1994) Int. Ophth. Clinics 34:121-148.
Simorre-Pinatel et al. (1994) Invest. Ophthalmol. Vis Sci. 35:3393-3400.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:1442.
Smith et al. (1994) Invest. Ophthalmol. Vis. Sci. 35:101-111.
Focus (Jan. 6, 1995).
Ophthalmology World News (1995) p. 26.
Ophthalmology Times (Jan. 16-22, 1995).

Affiliated with

Also associated with

Rating

Inhibition of neovascularization using vegf-specific oligonucleo does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of neovascularization using vegf-specific oligonucleo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of neovascularization using vegf-specific oligonucleo will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-686446